Delivery Order SPE2DB20D1100-SPE2DB25FE1W7
Award Date 8/20/25
Potential Completion Date 9/11/25
Potential Value $18K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $3,581.62 to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 15, 2025, and represents a non-set-aside procurement. AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania serves as the place of performance for this medical supply delivery. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,790.80 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price delivery order, issued on August 8, 2025, with an ultimate completion date of August 29, 2025, represents a competitive award with no set-aside designation. The award was fulfilled by AmerisourceBergen's Corporate Office located in Conshohocken, Pennsylvania, the...
- The Defense Logistics Agency awarded a $10,744.80 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract includes no set-aside designation,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,197.65 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial, a rabies immunoglobulin product, with performance in Conshohocken, Pennsylvania. This competitively awarded, firm fixed-price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- This delivery order, awarded on August 7, 2025, to AmerisourceBergen Drug Corp represents a $8,954.05 firm fixed-price procurement of HYPERRAB 300 Unit/mL rabies immunoglobulin. The award was issued by the Medical Supply Chain, a Defense Logistics Agency entity responsible for pharmaceutical and medical supply procurement to support military and federal healthcare systems. As a child order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for HYPERRAB 300 Unit/mL, a rabies immunoglobulin product, with a ceiling value of $18,711.54. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a non-competitive set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award falls under a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product commonly used for post-exposure prophylaxis. This firm fixed price delivery order, valued at $10,744.80, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 through December 2026. The contract was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 3mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price delivery order carries a ceiling value of $6,616.74 and is scheduled for completion by August 21, 2025. The award was made on a competitive, non-set-aside basis to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company...
- The Department of Defense's Medical Supply Chain awarded a delivery order valued at $13,513.89 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL, a rabies immunoglobulin product. This firm fixed-price delivery order, issued on August 18, 2025, is scheduled for ultimate completion by September 9, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award utilized competitive procedures with no set-aside designation, reflecting AmerisourceBergen's...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $18,711.54 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of HYPERRAB 300 Unit/ML (1 unit). This firm fixed-price delivery order, with completion scheduled for August 28, 2025, represents a competitive award with no set-aside designation. The contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion...